相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition
Albana Gattelli et al.
ONCOGENE (2018)
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
James X. Sun et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
Dennis Plenker et al.
CLINICAL CANCER RESEARCH (2018)
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data
Hossein Khiabanian et al.
JCO PRECISION ONCOLOGY (2018)
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Gang G. Li et al.
CLINICAL CANCER RESEARCH (2017)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Sorafenib for the treatment of breast cancer
Giuseppe Bronte et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
Dennis Plenker et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh et al.
LANCET RESPIRATORY MEDICINE (2017)
Breast cancer statistics, 2017, racial disparity in mortality by state
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
Atul Kulkarni et al.
CLINICAL CANCER RESEARCH (2017)
High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis
Ryan J. Hartmaier et al.
CANCER RESEARCH (2017)
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers
Rana Hatem et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Drilon et al.
LANCET ONCOLOGY (2016)
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
Kim M. Hirshfield et al.
ONCOLOGIST (2016)
Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients
Paola Griseri et al.
ONCOTARGET (2016)
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts
Elena Andreucci et al.
ONCOTARGET (2016)
Drosophila Cancer Models Identify Functional Differences between Ret Fusions
Sarah Levinson et al.
CELL REPORTS (2016)
Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy
Samuel J. Klempner et al.
JAMA ONCOLOGY (2016)
A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.
Se-Hoon Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient
Siraj M. Ali et al.
CASE REPORTS IN ONCOLOGY (2016)
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication
Christina S. Baik et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI
Samuel J. Klempner et al.
LUNG CANCER (2015)
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
Thomas Wiesner et al.
NATURE (2015)
Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma
A. L. Silva et al.
ENDOCRINE (2015)
Distinct Pathways Regulated by RET and Estrogen Receptor in Luminal Breast Cancer Demonstrate the Biological Basis for Combination Therapy
Philip M. Spanheimer et al.
ANNALS OF SURGERY (2014)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer
Philip M. Spanheimer et al.
CLINICAL CANCER RESEARCH (2014)
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers
Jamunarani Veeraraghavan et al.
NATURE COMMUNICATIONS (2014)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan
NATURE REVIEWS CANCER (2014)
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Kiyoshi Okamoto et al.
CANCER LETTERS (2013)
GDNF-RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors
Andrea Morandi et al.
CANCER RESEARCH (2013)
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Luca Mologni et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
The New Kid on the Block: RET in Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2013)
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Alexander Drilon et al.
CANCER DISCOVERY (2013)
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer
Rui Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism
Maria Grazia Borrello et al.
ENDOCRINE-RELATED CANCER (2011)
Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells
Masao Nakagawa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro
Marina Muzza et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC
Karin Frank-Raue et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Genomic instability in breast cancer: Pathogenesis and clinical implications
Kevin A. Kwei et al.
MOLECULAR ONCOLOGY (2010)
Transcript Level Modulates the Inherent Oncogenicity of RET/PTC Oncoproteins
Douglas S. Richardson et al.
CANCER RESEARCH (2009)
A role for glial cell-derived neurotrophic factor-induced expression by inflammatory cytokines and RET/GFRα1 receptor up-regulation in breast cancer
Selma Esseghir et al.
CANCER RESEARCH (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases
Pia Runeberg-Roos et al.
ANNALS OF MEDICINE (2007)
An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma
Daniela Cordella et al.
ENDOCRINE-RELATED CANCER (2006)
RET tyrosine kinase signaling in development and cancer
E Arighi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
KD Miller et al.
CLINICAL CANCER RESEARCH (2005)
Expression of a truncated form of the c-kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer
MP Paronetto et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines
ME Ray et al.
CANCER RESEARCH (2004)
Chronic expression of RET/PTC3 enhances basal and insulin-stimulated Pl3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells
E Miyagi et al.
MOLECULAR CARCINOGENESIS (2004)
Autoinhibition of the Kit receptor tyrosine kinase by the cytosolic juxtamembrane region
PM Chang et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
C Tognon et al.
CANCER CELL (2002)
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane
C Monaco et al.
ONCOGENE (2001)
分享论文
